Navigation Links
Sirnaomics Received NIH SBIR Grant for Developing Its Scarless Wound Healing siRNA Therapeutics

GAITHERSBURG, Md., June 25, 2012 /PRNewswire/ -- Sirnaomics, Inc. ( announced today that the company has been awarded another NIH SBIR (Small Business Innovation Research) grant for developing its small interfering RNA (siRNA) therapeutic product STP705 to improve skin wound healing with minimized scar formation.  This funding will further enhance the company's effort for perfection of its nanoparticle-based siRNA delivery systems and speed up the IND enabling studies for STP705.  Sirnaomics' multi-targeted siRNA therapeutics utilizing its nanoparticle delivery technologies represents a unique approach for realizing the advantage of siRNA-based drugs. Since its establishment, Sirnaomics has been successfully awarded five NIH SBIR grants in addition to other government grant funding. 

Sirnaomics is a leading biopharmaceutical company in the discovery and development of siRNA therapeutics.  The company's mission is to advance siRNA therapeutics by using its proprietary multi-targeted siRNA design and screening together with nanoparticle-mediated siRNA delivery vehicles.  Through in-house efforts and collaborations, Sirnaomics has developed nanoparticle-based siRNA delivery systems in three generations: the self-assembled nanoparticles (1st), the ligand-directed nanoparticles (2nd)  and the infrared-activated nanoparticles (3rd), for various types of therapeutic applications.  Based on these two technology platforms, Sirnaomics has developed an enriched pipeline of siRNA therapeutic product candidates, including STP705 for improvement of skin wound healing with minimized scar formation, STP601 for treatment of ocular AMD/diabetic retinopathy, STP702 for treatment of respiratory influenza viral infection, STP909 for treatment of HPV infection/cervical cancer, and candidates for several other therapeutic indications. 

"Receiving an NIH SBIR grant for development of siRNA therapeutics to improve skin scarless wound healing clearly demonstrates the scientific merits of Sirnaomics' siRNA therapeutic program," said Dr. Patrick Y. Lu, President and CEO of the company. "The collaboration among scientists and clinicians from Sirnaomics, Johns Hopkins University and Navy Medical Research Center provided a solid foundation for the success of such a novel therapeutic approach." Dr. Lu further emphasized that continuous government funding is critical for the growth of a therapeutic product company like Sirnaomics, especially in the current financial environment.

According to a report from The Mattson Jack Group, market for reduction of scarring on skin is about US$4 billion a year. Some 42 million surgery-patients in the U.S. each year could potentially benefit from the pharmaceuticals that can improve wound healing and minimize scar formation. There are 41.8 million surgical procedures each year in Europe and 70 million procedures annually in the United States involving skin wounds, which could benefit from these pharmaceuticals.  Currently there is no approved pharmaceutical of such available in the market in either U.S. or Europe. Sirnaomics has discovered and developed its first-in-class siRNA therapeutic candidate, STP705, to address this unmet clinical need.  Currently, this novel drug compound is under intensive IND-enabling studies in both U.S. and China.

Sirnaomics, Inc. is a privately held Delaware corporation headquartered in Gaithersburg, Maryland, U.S.A. Established in 2007 by a group of leading scientists in the field of RNAi technology, the company is pursuing the mission of advancing RNAi technology with novel multi-targeted therapeutic development. In 2008, the company established its subsidiary in Suzhou, China to expand its R&D capacity and potential market. Members of the senior management team bring over 90 years of combined experience in the biopharmaceutical, financial and business management industries. Supported with funding from angel investors, corporate partnerships, government grants and venture capitals, Sirnaomics has developed a strong portfolio of intellectual properties with an enriched product pipeline. The therapeutic areas of interest include regenerative medicine (wound healing), diabetic complications, respiratory viral infection, HPV and cervical cancer, among others. CONTACT: George Ji, Senior VP for Corporate Developmentgji@sirnaomics.comSirnaomics, Inc.Tel: +1-301-740-1730Fax: +1-301-740-1731

SOURCE Sirnaomics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ReShape Medical Appoints Robert E. Grant to Board of Directors
2. Community Foundation Announces $2.6 Million In Grants From Centinela Medical Funds
3. Sorrento Therapeutics Awarded Third Phase I STTR Grant
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Brain Research Foundation Announces Grant To Study Concussive Events Among Grade School Children
6. Oramed Pharmaceuticals Granted Core Technology Patent in New Zealand
7. QRxPharma Granted Additional US Patent on MoxDuo®
8. Health Diagnostic Laboratory, Inc. Provides Grant to Support National Lipid Association, Sponsors 2012 Annual Scientific Sessions in Scottsdale, Arizona
9. BiO2 Medical Granted CE Mark for the Angel™ Catheter, the First IVC Filter with a Prophylactic Use Indication
10. Broad Patent Protection Granted for iBio Immunomodulator
11. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
Post Your Comments:
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... recently awarded their highest ... . , Millions of individuals in the United States and Canada wear eyeglasses. Once ... to both correct vision and make a fashion statement. Even celebrities use glasses as ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
Breaking Medicine News(10 mins):